Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore

•Novartis India Ltd acquires 'Minipress' trademark from Pfizer for ₹1,250 crore.

•Transaction involves trademarks and related IP rights in India, with signing and closing scheduled simultaneously.

•Minipress XL, used for hypertension and BPH, recorded ₹228.6 crore revenue in July 2026, with 6.3% CAGR since 2022.

•Pfizer Ltd to discontinue Minipress XL marketing, distribution, and sale due to Pfizer Inc USA's decision to discontinue manufacture.